BACKGROUND: Histologic grade is said to be the most important prognostic factor in adult soft tissue sarcomas (STS), but most grading systems have been tested in the overall sarcoma group and the predictive value of histologic grade needs to be assessed specifically for each of the histologic categories. METHODS: From 1980 to 1994, 1240 nonmetastatic patients were entered in the French STS database. The following parameters were studied: patient's age and gender, previous history, tumor location, size and depth, neurovascular or bone involvement (NBI), histologic type and subtype, and grade (the French Federation of Cancer Centers [FNCLCC] system). Median follow-up for the survivors was 88 months; only 5% of patients were lost to follow-up. The authors performed univariate and multivariate analyses for metastasis-free survival for the overall sarcoma group and for every main histologic type. RESULTS: In order of importance, parameters were respectively retained as independent predictors of metastasis as follows: grade, tumor size, NBI and tumor depth for the overall group, grade and NBI for malignant fibrous histiocytomas (n = 349), tumor size, histologic subtype and grade for liposarcomas (n = 188), NBI, grade and tumor size for leiomyosarcomas (n = 148), grade and NBI for synovial sarcomas (n = 125), grade for unclassified sarcomas (n = 140), and sarcomas of other types (n = 158). No parameter was significant for malignant schwannomas (n = 72) or for rhabdomyosarcomas (n = 60). CONCLUSION: In this study, histologic grade appeared as an independent predictor of metastasis development in the main histologic types of adult STS, with the exception of malignant schwannomas and rhabdomyosarcomas. Copyright 2001 American Cancer Society.
BACKGROUND: Histologic grade is said to be the most important prognostic factor in adult soft tissue sarcomas (STS), but most grading systems have been tested in the overall sarcoma group and the predictive value of histologic grade needs to be assessed specifically for each of the histologic categories. METHODS: From 1980 to 1994, 1240 nonmetastatic patients were entered in the French STS database. The following parameters were studied: patient's age and gender, previous history, tumor location, size and depth, neurovascular or bone involvement (NBI), histologic type and subtype, and grade (the French Federation of Cancer Centers [FNCLCC] system). Median follow-up for the survivors was 88 months; only 5% of patients were lost to follow-up. The authors performed univariate and multivariate analyses for metastasis-free survival for the overall sarcoma group and for every main histologic type. RESULTS: In order of importance, parameters were respectively retained as independent predictors of metastasis as follows: grade, tumor size, NBI and tumor depth for the overall group, grade and NBI for malignant fibrous histiocytomas (n = 349), tumor size, histologic subtype and grade for liposarcomas (n = 188), NBI, grade and tumor size for leiomyosarcomas (n = 148), grade and NBI for synovial sarcomas (n = 125), grade for unclassified sarcomas (n = 140), and sarcomas of other types (n = 158). No parameter was significant for malignant schwannomas (n = 72) or for rhabdomyosarcomas (n = 60). CONCLUSION: In this study, histologic grade appeared as an independent predictor of metastasis development in the main histologic types of adult STS, with the exception of malignant schwannomas and rhabdomyosarcomas. Copyright 2001 American Cancer Society.
Authors: Lemuel Leon Dent; Cesar Yamil Cardona; Michael Clause Buchholz; Roosevelt Peebles; Julie Denise Scott; Derrick Jerome Beech; Billy Ray Ballard Journal: World J Gastroenterol Date: 2010-10-28 Impact factor: 5.742
Authors: Luca Clemente; Derek S Boeldt; Mary A Grummer; Mayu Morita; Terry K Morgan; Greg J Wiepz; Paul J Bertics; Ian M Bird Journal: Mol Cell Endocrinol Date: 2019-09-21 Impact factor: 4.102
Authors: Adriana C Gamboa; Cecilia G Ethun; Jeffrey M Switchenko; Joseph Lipscomb; George A Poultsides; Valerie Grignol; J Harrison Howard; T Clark Gamblin; Kevin K Roggin; Konstantinos Votanopoulos; Ryan C Fields; Shishir K Maithel; Keith A Delman; Kenneth Cardona Journal: J Am Coll Surg Date: 2019-08-01 Impact factor: 6.113
Authors: Jörg Thomas Hartmann; M Horger; T Kluba; A Königsrainer; P de Zwart; C Hann von Weyhern; F Eckert; W Budach; C Bokemeyer Journal: Invest New Drugs Date: 2013-10-04 Impact factor: 3.850
Authors: Darya Buehler; Stephanie R Rice; John S Moody; Patrick Rush; Gholam-Reza Hafez; Steven Attia; B Jack Longley; Kevin R Kozak Journal: Am J Clin Oncol Date: 2014-10 Impact factor: 2.339
Authors: Inigo Espinosa; Andrew H Beck; Cheng-Han Lee; Shirley Zhu; Kelli D Montgomery; Robert J Marinelli; Kristen N Ganjoo; Torsten O Nielsen; C Blake Gilks; Robert B West; Matt van de Rijn Journal: Am J Pathol Date: 2009-05-14 Impact factor: 4.307